This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...